These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10996837)

  • 1. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
    Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
    Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases.
    Zompi S; Tulliez M; Conti F; Leblond V; Gaulard P; Blanche P; Durand F; Ghandi D; Dreyfus F; Louvel A; Calmus Y; Bouscary D
    J Hepatol; 2000 Mar; 32(3):521-7. PubMed ID: 10735625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Post-transplantation lymphoproliferative disorder in childhood].
    Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
    Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
    Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB
    Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
    Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L
    J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
    Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
    Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab treatment for posttransplantation lymphoproliferative disorder after small bowel transplantation.
    Nishida S; Kato T; Burney T; Levi D; Nery J; Madariaga J; Mittal N; Weppler D; Ruiz P; Tzakis A
    Transplant Proc; 2002 May; 34(3):957. PubMed ID: 12034259
    [No Abstract]   [Full Text] [Related]  

  • 13. [Post-transplant lymphoproliferative disorders: a report of two cases].
    Wang ZM; Wang LJ; Yu XR; Xu LM
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):639-40. PubMed ID: 17134580
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment.
    McGhee W; Mazariegos GV; Sindhi R; Abu-Elmagd K; Reyes J
    Transplant Proc; 2002 May; 34(3):955-6. PubMed ID: 12034258
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
    Meng HT; Li Y; Liu JH; Xu GX; Teng XD
    Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
    O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
    Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
    Iu LP; Yeung JC; Loong F; Chiang AK
    Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
    Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
    J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.